Search Results

The AutoDELFIA Neonatal IRT kit is intended for the quantitative determination of human immunoreactive trypsin(ogen) (IRT) in blood specimens dried on filter paper as an aid in screening newborns for cystic fibrosis using the 1235 AutoDELFIA® automatic immunoassay system.

The AutoDELFIA Neonatal IRT assay is a solid phase, two-site fluoroimmunometric assay based on the direct sandwich technique in which two monoclonal antibodies (derived from mice) are directed against two separate antigenic determinants on the IRT molecule. Calibrators, controls and test specimens containing IRT are reacted simultaneously with immobilized monoclonal antibodies directed against a specific antigenic site on the IRT molecule and europium-labeled monoclonal antibodies (directed against a different antigenic site) in assay buffer. The assay buffer elutes IRT from the dried blood on filter paper disks. The complete assay requires only one incubation step. Enhancement Solution dissociates europium ions from the labeled antibody into solution where they form highly fluorescent chelates with components of the Enhancement Solution. The fluorescence in each well is then measured. The fluorescence of each sample is proportional to the concentration of IRT in the sample.

The provided text describes a 510(k) premarket notification for the AutoDELFIA Neonatal IRT kit. This submission focuses on demonstrating substantial equivalence to a predicate device, rather than providing a detailed study report with specific acceptance criteria and performance data in the format typically used for AI/ML device evaluations. As such, many of the requested fields for AI/ML device studies are not directly applicable or explicitly stated in this document.

However, I can extract information related to the device's analytical performance characteristics, which serve as a form of acceptance criteria for this type of in-vitro diagnostic device.

Here's an attempt to populate the table and answer the questions based on the provided text, indicating where information is not available.

1. Table of Acceptance Criteria and the Reported Device Performance

For this in-vitro diagnostic device, "acceptance criteria" are generally established by demonstrating performance characteristics that are comparable to or better than a legally marketed predicate device, and that meet the required analytical performance for its intended use.

Note on "Acceptance Criteria": For this 510(k) submission, the "acceptance criteria" are implied to be achieving analytical performance characteristics that are comparable to or improved from the predicate device, thereby demonstrating substantial equivalence. The table shows that the new device generally performs comparably or better (e.g., lower LoB, explicit linearity claim, more detailed precision data, and a wider range of concentrations with good precision).

Regarding the study proving the device meets the acceptance criteria:

The document describes the submission as a 510(k) for an in-vitro diagnostic kit. The "study" here refers to the analytical performance evaluation conducted by the manufacturer to demonstrate substantial equivalence to the predicate device. The information provided is a summary of the device's analytical characteristics.

2. Sample size used for the test set and the data provenance:

• Sample Size: Not explicitly stated in terms of number of individual patient samples. The precision data lists several concentration levels (e.g., 16.7 ng/mL, 22.5 ng/mL, etc.), implying multiple measurements were taken at each level. The cross-reactivity and hook effect studies would have involved specific spiked samples.
• Data Provenance: Not explicitly stated (e.g., country of origin). It's an in-house analytical validation, likely conducted at the manufacturer's facility. It is a retrospective analysis of laboratory-prepared samples or collected blood spots rather than a prospective clinical study involving external patient recruitment.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

• This question is more applicable to AI/ML devices that rely on expert interpretation for ground truth. For this in-vitro diagnostic assay, the "ground truth" for reported values (e.g., IRT concentration) is established by the analytical method itself and calibration against known standards. There's no mention of external expert consensus for establishing ground truth for the analytical performance data.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

• Not applicable for this type of analytical performance study of an in-vitro diagnostic kit. Adjudication methods like 2+1 or 3+1 are typically used in clinical studies where multiple human readers interpret medical images or clinical data, and a disagreement resolution process is needed to establish a definitive ground truth.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

• Not applicable. This is not an AI/ML device designed to assist human readers. It's an automated immunoassay system for quantitative measurement.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

• No, this is not an AI/ML algorithm. It is an automated immunoassay kit where the "algorithm" is the biochemical reaction and the instrument's measurement and calculation of IRT concentration. The device operates in a standalone analytical capacity to measure IRT.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc):

• The ground truth for the analytical performance characteristics (such as concentration, linearity, limit of blank, limit of detection, cross-reactivity, hook effect, and precision) would be established by:
  • Reference materials/known standards: For calibration, linearity, and determining accurate concentrations.
  • Spiked samples: For cross-reactivity and hook effect studies where known interferents or high concentrations are added.
  • Repeated measurements: For precision studies.

8. The sample size for the training set:

• Not explicitly stated, and the concept of a "training set" as understood in AI/ML is not directly applicable. For this type of device, development involves optimizing the assay components and conditions, which is an iterative process using various samples (e.g., patient samples, spiked samples, controls) but not typically referred to as a discrete "training set" in the AI/ML context.

9. How the ground truth for the training set was established:

• As above, the concept of a "training set" with established ground truth in the AI/ML sense is not relevant here. Ground truth for internal development and optimization would be based on the known biochemical properties of the reagents, reference standards, and performance evaluation criteria.

Ask a specific question about this device

The GSP Neonatal IRT kit is intended for the quantitative determination of IRT in blood specimens dried on filter paper as an aid in screening newborns for cystic fibrosis using the GSP® instrument.

The GSP Neonatal IRT assay is a solid phase, two-site fluoroimmunometric assay based on the direct sandwich technique in which two monoclonal antibodies (derived from mice) are directed against two separate antigenic determinants on the IRT molecule. Calibrators, controls or test specimens containing IRT are reacted simultaneously with immobilized monoclonal antibodies directed against a specific antigenic site on the IRT molecule and europium-labeled monoclonal antibodies (directed against a different antigenic site) in assay buffer. The assay buffer elutes IRT from dried blood on filter paper disks. The complete assay requires only one incubation step. DELFIA Inducer dissociates europium ions from the labeled antibody into solution where they form highly fluorescent chelates with components of the DELFIA Inducer. The fluorescence in each well is then measured. The fluorescence of each sample is proportional to the concentration of IRT in the sample.

The provided text describes the GSP Neonatal IRT kit, a device for screening newborns for cystic fibrosis. It compares the new device to a predicate device (AutoDELFIA Neonatal IRT kit) and presents information on its performance characteristics.

Here’s a breakdown of the acceptance criteria and study information:

1. Table of Acceptance Criteria and Reported Device Performance

Study Proving Device Meets Acceptance Criteria:

The document describes a substantial equivalence claim, not a separate clinical study with independent acceptance criteria beyond demonstrating equivalence to the predicate device. The "study" here is the comparison and characterization of the new device's performance against the established predicate device (AutoDELFIA Neonatal IRT kit, K0003668). The acceptance criteria are largely implicitly defined by the performance characteristics of the predicate device, where the new device is shown to have similar or improved performance in analytical parameters.

2. Sample Size Used for the Test Set and Data Provenance

The provided text does not explicitly state a sample size for a test set in the context of a clinical study. The performance characteristics reported (e.g., precision, analytical sensitivity, measuring range) are typically derived from analytical verification and validation studies in a laboratory setting.

• Sample Size: Not explicitly stated for a "test set" in a clinical context. The precision data lists various IRT concentrations tested, and each CV% (Coefficient of Variation) would have been derived from replicate measurements.
• Data Provenance: The document does not specify the country of origin of the data or whether the studies generating these performance characteristics were retrospective or prospective. It describes the device's analytical performance.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

N/A. This is an in-vitro diagnostic device for measuring a biomarker (IRT). The "ground truth" for its performance is based on analytical measurements and comparison to a known standard, not on expert clinical evaluation or interpretation of images.

4. Adjudication Method for the Test Set

N/A. Adjudication methods like 2+1 or 3+1 are typically used in clinical studies involving interpretation of data (e.g., images) by multiple human readers, not in the analytical validation of an in-vitro diagnostic assay measuring a biomarker.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done

N/A. An MRMC study is not applicable to the analytical performance evaluation of this type of in-vitro diagnostic device. This device measures a quantitative biomarker and does not involve human interpretation of cases or "readers" in the traditional sense, nor does it aim to improve human reader performance.

6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was Done

The device itself is a "standalone" assay in the sense that it quantifies IRT levels directly from a blood spot sample using an instrument. There is no human interpretation of an algorithm output, but rather a direct measurement that aids in screening. The GSP® instrument performs the assay automatically.

7. The Type of Ground Truth Used

The ground truth for the device's performance (especially for parameters like measuring range, sensitivity, and precision) would be established by:

• Reference materials/calibrators: Samples with known concentrations of IRT (calibrated using gravimetric methods, as mentioned).
• Established analytical methods: Comparison to recognized analytical techniques for IRT measurement.
  This is not "expert consensus, pathology, or outcomes data" in the clinical sense, but rather a robust analytical validation against known standards.

8. The Sample Size for the Training Set

N/A. This document pertains to an in-vitro diagnostic kit for measuring a biomarker, not a machine learning or AI algorithm that requires a "training set" in the computational sense. The device's performance is based on its chemical and immunological assay design.

9. How the Ground Truth for the Training Set was Established

N/A. As stated above, this is not an AI/ML device that uses a "training set."

Ask a specific question about this device

The AutoDELFIA® Neonatal IRT L kit is intended for the quantitative determination of human immunoreactive trypsin (ogen) (IRT) in blood specimens dried on filter paper as an aid in screening newborns for cystic fibrosis using the 1235 AutoDELFIA® automatic immunoassay system.

The AutoDELFIA Neonatal IRT assay is a solid phase, two-site fluoroimmunometric assay based on the direct sandwich technique in which two monoclonal antibodies (derived from mice) are directed against two separate antigenic determinants on the IRT molecule. Standards, controls and test specimens containing IRT are reacted simultaneously with immobilized monoclonal antibodies directed against a specific antigenic site on the IRT molecule and europium -labeled monoclonal antibodies (directed against a different antigenic site) in assay buffer. The assay buffer elutes IRT from the dried blood spots on the filter paper discs. The complete assay requires only one incubation step. Enhancement Solution dissociates europium ions from the labelled antibody into solution where they form highly fluorescent chelates with components of the Enhancement Solution. The fluorescence in each well is the measured. The fluorescence of each sample is proportional to the concentration of IRT in the sample.

This document describes the AutoDELFIA Neonatal IRT L kit, an in vitro diagnostic device used for screening newborns for cystic fibrosis by quantitatively determining immunoreactive trypsin(ogen) (IRT) in dried blood specimens. The submission seeks to demonstrate substantial equivalence to a previously cleared device, the AutoDELFIA Neonatal IRT kit (K003668).

Here's a breakdown of the requested information based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria are implicitly derived from the comparison of the new device (AutoDELFIA Neonatal IRT L kit, B022-112) with the predicate device (AutoDELFIA Neonatal IRT kit, B005-112). The goal is to show equivalent analytical performance characteristics.

Note: The text explicitly states "The analytical performance characteristics of the two kits are equivalent" implying that the performance of the new device matching or being comparably close to the predicate device serves as the acceptance criteria. For the IRT distribution, the differences are noted, suggesting that while not identical, they are considered within acceptable equivalence for substantial equivalence.

2. Sample Size Used for the Test Set and the Data Provenance

The document does not explicitly state the sample size used for the test set for the studies on precision, limit of blank, linearity, hook effect, or IRT distribution.

• Data Provenance: The document does not specify the country of origin for the data or whether the studies were retrospective or prospective.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts

This information is not provided in the document. The studies described are analytical performance studies of an IVD kit, not studies requiring expert interpretation of results for ground truth. The "ground truth" for these tests would typically be defined by reference methods or established statistical analysis of the assay's performance characteristics.

4. Adjudication Method for the Test Set

Adjudication methods (e.g., 2+1, 3+1) are typically used in clinical studies where multiple readers or experts assess cases. This document describes analytical performance studies of a diagnostic assay kit. Therefore, an adjudication method is not applicable and not mentioned.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not done. This document describes the analytical validation of an in vitro diagnostic kit, not a study involving human readers interpreting results with and without AI assistance.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

The device is an automated immunoassay system (AutoDELFIA® automatic immunoassay system) that performs quantitative measurements. The performance data presented (precision, limit of blank, linearity, hook effect, IRT distribution) are standalone performance metrics of the assay kit itself, without human interpretation as part of the primary measurement. Human intervention would be for laboratory procedures and interpretation of the quantitative result against clinical cut-offs, but the device performance itself is standalone in terms of generating the IRT concentration.

7. The Type of Ground Truth Used

For the analytical performance characteristics:

• Precision: Established by repeated measurements.
• Limit of blank: Determined statistically from blank sample readings.
• Linearity: Assessed by analyzing samples of known, serially diluted concentrations.
• Hook effect: Investigated using samples with very high IRT concentrations.
• IRT distribution in newborns: This likely represents observed data from a population of newborns, which serves as the "ground truth" for reflecting the typical range of IRT in the target population. However, the exact method for establishing this, beyond sample analysis, is not detailed.

In essence, the "ground truth" for these studies is derived from analytical measurements and statistical analysis against reference materials or established methods, rather than expert consensus, pathology, or outcomes data in a clinical sense.

8. The Sample Size for the Training Set

The document describes the validation of an IVD kit, not an AI/ML algorithm that typically has a "training set." Therefore, the concept of a "training set sample size" as commonly understood in AI/ML is not applicable to this submission. The kit is based on established fluoroimmunometric assay principles and monoclonal antibodies.

9. How the Ground Truth for the Training Set Was Established

As noted in point 8, the concept of a "training set" in the AI/ML context is not applicable. The assay's performance is established through calibration and validation studies using known standards and samples, similar to how analytical methods are developed and validated in general.

Ask a specific question about this device